| 
    Connections: ABN Virtual Meeting 2021 
    
        
            The live portion of the ABN Annual Meeting ‘Connections 2021’ took place in evening sessions on 29 April and the 6, 13 May, culminating in 2 full day meetings on 20 and 21 May. All sessions were recorded and will remain accessible to delegates
                on catch-up via the conference app until 30 August 2021. There are 36 CPD points allocated to the meeting. Members wishing to register for the recorded portion of the meeting should use the link in the red bar above. Access Here All members may access the Medallist lecture, the President's lecture and the AGM
                 
            
                
                    
                    
                    
                    
                        
                            
                            
                                
                                    
                                 
                                    
                                        Evening Sessions29th April, 6th May, 13th May (7pm - 8pm)  
                                        Special Interest Group and Poster Sessions: 3 parallel sessions per evening 
                                29 April 
                                    
                                        
                                            Welcome and Introduction: David Burn, ABN PresidentJazz Pharmaceuticals:(5 minutes) Obstructive sleep apnoea & excessive daytime sleepiness in MS & other neurological conditions: Gavin Giovannoni, Adrian Williams
                                                SIG 1: MS & Neuroinflammation & posters
                                                    
                                                        Chair:Tarunya Arun
                                                            Case based discussion in neurosarcoidosis and MS registries and trials project updatesSARS -CoV2 vaccinations in MS-a moving target: Klaus Schmierer UK MS register sub study: COVID-19 and Multiple Sclerosis: Nikos EvangelouUK Consortium of MS Trials and registries: Emma Tallantyre 
 Posters(4)
                                                            Ten year follow-up surveillance of paediatric Acquired Demyelinating Syndromes (ADS) in the UK: Omar Abdel-MannanSustained reduction of disability and cognitive decline with long-term siponimod in EXPAND active SPMS patients: Gavin GiovannoniRemyelination in people with MS due to an RXR agonist is age-dependent: Chris McMurranDisability and quality of life changes in people with MS (pwMS) throughout the COVID-19 pandemic: Rod Middleton
SIG 2: Functional Disorders 
                                                    Chair:Markus Reuber
                                                        Introduction to FCD: diagnosis and concepts: Laura McWhirterEpidemiology: Harriet BallUsing language to assess memory complaints: Daniel Blackburn 
 SIG 3: Headache & posters
                                                    Chair: Mark Weatherall
                                                        What's new in disorders of CSF pressure?
                                                            Idiopathic intracranial hypertension (IIH) Alex SinclairSpontaneous intracranial hypotension (SIH) Manjit MatharuQ&A on management of IIH and SIH 
 Posters (4)
                                                        Switching CGRP monoclonal antibodies for chronic migraine: real-world outcomes of 37 episodes: Manjit MatharuHow much weight loss is required to reduce intracranial pressure in idiopathic intracranial hypertension?Susan MollanEfficacy of Fremanezumab in Chronic Migraine Patients With Inadequate Response to ≥3 Preventive Medication Classes: Eoin SherwinEvaluation of 3 Month Data for the Use of Erenumab for Chronic Migraine in Glasgow: Krishna Dani   
                                6 May 
                                    
                                        
                                            Welcome: Tom Warner, ABN President Elect
                                                SIG 4: Movement Disorders& posters
                                                    
                                                        Chair:Mark Edwards
                                                            How should we respond to negative neuroprotection clinical trials in Parkinson’s disease? New models for clinical trials: Camille Caroll & Tom FoltynieLive poster presentations chaired by Mark Edwards 
 Posters(4)
                                                            Functional genomics and transcriptomics further characterise and potentially improve diagnostic yield of hereditary ataxias: Zhongbo ChenEvaluating a Home-Based Care Pathway for People with Parkinson's Disease: Emma KingCortical sensorimotor representations remain normal in musicians’ dystonia despite global deficit in dexterity: Anna SadnickaEmerging parkinsonism in the PREDICT-PD cohort after 5-year follow-up: Cristina Simonet
 Two movement disorder video case presentations 
SIG 5: Cognitive Disorders 
                                                    Chair: Daniel Blackburn
                                                        Local experience of CSF biomarkers for AD: Akram Hosseini FTD or not FTD that is the question: Tobias LangheinrichLive poster presentations chaired by Daniel Blackburn 
 Posters(4)
                                                        Validation of the Diagnostic Criteria for Sporadic Creutzfeldt-Jakob Disease: Neil WatsonA review of the performance of referring centres in diagnosing sCJD on MRI: Danielle SequeiraMachine learning accurately determines the population prevalence of Alzheimer's disease based on microbiome profile: Amedra BasgaranNeuroanatomical signatures of genetic risk for Alzheimer's Disease in healthy adults: Cameron Watson
 SIG 6: Sustainability & posters
                                                    Chair: Sui Wong
                                                        How neurologists can help make life and health services sustainable: Richard Smith (15-20 min talk + discussion)Sharing best-practices and initiatives:
                                                            Short Term Feasibility Study in Epilepsy (5 min): Sanjay SisodiyaAcademia & Sustainability (5 min): Rustam Al-Shahi SalmanOn panel: John WoolmoreBehind the scenes for Q&A: Jan Coeburgh 
 Posters (4)
                                                        Listen to Learn: Podcast-Series for IMT Induction at National Hospital for Neurology and Neurosurgery (NHNN): Sabahat IqbalReducing the environmental impact of junior doctors at Queen Square: Dominic WilkinsThe future of outpatient appointments – Do patients with epilepsy prefer remote consultations? Smriti BoseExperiences of remote consulting for neurologists and patients during the COVID-19 pandemic – a national survey: Maria Stavrou   
                                13 May 
                                    
                                        
                                            Welcome: Richard Davenport, ABN Meeting Secretary
                                                Poster session 1
                                                    Sofia Eriksson, Keith Muir & Huw Morris
                                                        Language Decline Following White Matter Tract Damage During Anterior Temporal Lobe Resection in Language Dominant Hemisphere: Lawrence BindingUtilising optical coherence tomography measures as surrogates for raised intracranial pressure in idiopathic intracranial hypertension: Susan MollanSafety, β-sarcoglycan expression and functional outcomes from systemic gene transfer of rAAVrh74.MHCK7.SGCB in LGMD2E/R4: James RichardsonThe National Audit of Seizure Management in Hospitals – Round 3 (NASH 3): Graham PowellInvestigatory Imaging in Autoimmune-Paraneoplastic Encephalitis: Arshia SeddighEarly lowering of blood pressure after acute intracerebral haemorrhage: systematic review and meta-analysis of patient-level data: Tom MoullaaliAutomated Classification of inter-ictal EEG in the diagnosis of epilepsy: Rohan AhmedA retrospective cohort study of cavernous sinus/ orbital apex syndromes presenting to Imperial College London: Aravindhan BaheerathanNew insight into dysautonomia in GFAP astrocytopathy: Yee Yen GohLimb girdle muscular dystrophy R12 (LGMD 2L, anoctaminopathy) presenting as refractory myositis: a case series: Italo MaragoMagnetic Resonance Spectroscopy to detect markers of brain injury in Tuberculous Meningitis (TBM): Angharad Davis
                                                         Poster session 2
                                                    Kevin Talbot, Holger Allroggen & Jon Sussman
                                                        Motor network remodelling in ALS and PLS: Evan EdmondSecondary syphilis presenting as acute unilateral visual loss in an immunocompetent elderly patient Srinivasa PaluriCerebral Venous Sinus Thrombosis and COVID-19: Causation or Coincidence?: James CrawfordA pilot study assessing choroidal thickness in frontotemporal dementia and motor neuron disease: Yingdi ChenIs it 'CLIPPERS'? Is it CNS Hemophagocytic Lymphohistiocytosis (HLH)?: Amitav ParidaPooled safety data from the risdiplam clinical trial development programme: Laurent Servais Investigating the molecular mechanisms of mutant C9orf72 human iPSC-derived astrocyte-mediated motor neuron deficits: Maria StavrouBaseline variation in commonly used inflammatory neuropathy clinical outcome measures: Ryan KehAutoimmune Autonomic Neuropathy on the Adie Spectrum – “Ross Syndrome?” Amedra BasgaranA qualitative study of patient perceptions of immunoglobulin treatment regimens for inflammatory neuropathy: Emma CallananAdherence to the ABN Guidelines for the Diagnosis and Management of Myasthenia Gravis: Joseph WelchThe prevalence and management of saliva problems in motor neuron disease: Iona Pearson Poster session 3
                                                    Ruth Dobson & Olga Ciccarelli
                                                        A case of natalizumab-related Progressive Multifocal Leukoencephalopathy treated with pembrolizumab: Rebecca RobinsonBenefit-risk of ofatumumab in treatment-naïve early relapsing multiple sclerosis patients: Dieter HaeringTreatment escalation in Secondary Progressive MS identified clinically and algorithmically in Relapsing Remitting (RR)MS: Richard NicholasParamagnetic Rims are a specific biomarker in Multiple Sclerosis: Christopher AllenUpdated analysis of pregnancy outcomes in a dimethyl fumarate exposure registry: David RogUK Multiple Sclerosis Register: Understanding the Gaps between Patient Outpatient Experiences and Preferences: Rachael  KeeVirtual Multiple Sclerosis (MS) clinics during a global pandemic: the patients’ perspective: Stephen RamsayImproving care of multiple sclerosis-associated uveitis in a tertiary referral centre in Northern Ireland: John LoganThe importance of the multidisciplinary team (MDT) in the management of patients with multiple sclerosis: Stephen RamsayA UK multicentre audit on the use of MRI in Multiple Sclerosis: Christopher AllenBeyond diagnosis - Patient perception of lumbar puncture for clinical management and/or research studies: Rebecca Robinson   
                            
                            
                                9am 
                                    
                                         Trainees' session
                                        Programme 
                                            9:15: Welcome9:30: My Top Mistake:
                                                David Nicholl, BirminghamRajiv Mohanraj, Manchester 10:45 - Parkinson's Disease:
                                                Psychiatric and cognitive syndromes/presentations in Parkinson’s:Acute presentations in PD/Care in late stage Parkinson’s, and managing the non-motor complications:
                                                    
                                                         Annette Schrag, Royal Free 11:45 - Q&A 12:05 - Close    
                                12:55pm 
                                    
                                         Introduction to ABN meetingDavid Burn   
                                1pm 
                                    
                                        Plenary Session 1Dementia: connecting the dots  
                                        Chair: Masud Husain 
                                            Biomarkers for dementia – There Will Be Blood:Advanced therapies for dementia: new revolution or false dawn?: 
                                2pm 
                                    
                                    
                                        
 
                                            Dementia & Epilepsy
                                                Chair: Chris Kipps1, Speech-in-noise perception is a marker of preclinical Alzheimer’s disease, Cameron Watson2, Population-based blood screening for pre-clinical Alzheimer’s disease: a British birth cohort at age 70 Ashvini Keshavan3, Deep phenotyping of frontal lobe epilepsy compared to other epilepsy syndromes Ryan Wee4, Pre-pregnancy and antenatal care of women with epilepsy Taief Miah Multiple Sclerosis
                                                Chair:Neil Robertson1, Retinoid-X receptor agonism promotes remyelination in relapsing-remitting multiple sclerosis: a phase 2 clinical trial William Brown2, UK Multiple Sclerosis service audit of 70 centres [4] Access to neuroradiology. Jeremy Hobart3, COVID-19 and multiple sclerosis: An updated report of the community-based longitudinal UK MS Register study. Afagh Garjani4, CSF-resident CD4+ T-cells display a distinct gene expression profile relevant to multiple sclerosis. James Hrastelj Movement Disorders
                                                Chair: Mark Edwards1, Biomarkers for brain injury and copper toxicity in Wilson's disease: A diffusion tensor imaging study. Samuel Shribman2, Improving the early diagnosis of corticobasal syndrome: a large clinico-pathological study Danielle Lux3, Lower lymphocyte count is associated with increased risk of Parkinson’s disease. Melanie Jensen4, Visual dysfunction predicts cognitive impairment and white matter degeneration in Parkinson’s disease. . Angeliki Zarkali Pharma Interlude (2:45pm) 
                                            GW Pharmaceuticals: Lennox-Gastaut syndrome: challenges in diagnosis and transitionNovartis: High Efficacy Treatment (HET) for MS in a changing worldKyowa Kirin: Management of Parkinson's disease: an update for clinicians 
                                            Muscle and Nerve
                                                Chair: Charlotte Dougan1, Andersen-Tawil Syndrome: Multi-System Deep Phenotyping of a large UK cohort. Vinojini Vivekanandam2, SUNFISH Part 2: 24-month efficacy and safety of risdiplam in Type 2/3 SMA. Giovanni Baranello3, Charcot-Marie-Tooth Disease secondary to biallelic mutations in SORD. Chris Record4, Good outcomes after aggressive treatment of immune checkpoint inhibitor related myasthenia gravis: a case series. Jamie Weaver Inflammatory and Neurogenetics
                                                Chair: Fiona Norwood1, Neurologic and radiographic findings associated with Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 (PIMS-TS). Omar Abdel-Mannan2, Genomic features specific to the human lineage are associated with neurological diseases and intelligence. Zhongbo Chen3, White matter Hyperintensities and Brain Microbleeds in Ataxia-Telangiectasia: the Cambridge cohort. May Yung Tiet4, L-arginine and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS): a systematic review. Yi Shiau Ng Neuro-Ophthalmology and TBI
                                                Chair: Arani Nitkunan1, Bariatric surgery versus community weight management intervention for idiopathic intracranial hypertension: A randomised controlled trial. Susan Mollan2, A randomised controlled, trial of the GLP-1 receptor agonist Exenatide in Idiopathic Intracranial Hypertension. James Mitchell3, Advanced blood and neuroimaging biomarkers of axonal injury after TBI in the prospective multi-centre BIO-AX-TBI study. Neil Graham4, Detailed evaluation of cognitive performance in Idiopathic Intracranial Hypertension and relevance of intracranial pressure. Olivia Grech Pharma Interlude (3:45pm) 
                                            Novartis Gene Therapies: Gene replacement therapy for spinal muscular atrophy (SMA) in clinical practiceJanssen: The many sides of MSArvelle: Is seizure freedom an impossible goal? 
                                4:45pm 
                                    
                                        Case CompetitionChair: Lucy Kinton 
                                            1, When the rhythm moves you, Anisha Doshi2, Yuletide tremor, twitches and tunes, Maryam Talaei3, A case of encephalopathy following a 10k run, Claire Carstairs4, Nuclear countdown, Daniel Rice-Wilson5, A man with Erb’s disease, Sara Leddy6, A localisation issue, Laura Midgley 
                            
                            
                            
                                9am 
                                    
                                        Plenary Session 2Connecting neurologists and complex therapies   
                                        Chair: Carolyn Gabriel 
                                            The neurological application of Bone marrow and Stem cell therapies:Charalampia Kyriakou, UCLWhy/how/when don't we use B cell depleting therapies earlier in neurology?:Katy Murray, Edinburgh 
                                10am 
                                    
                                        ABN MedallistNeuroinflammation: moving onNeil Scolding, Bristol Citation: Roger Barker 
                                10:45am 
                                    
                                        Pharma Interlude
                                            Teva: Monoclonals for Migraine: Our Experience.
                                                
                                                    Alex Sinclair, Mark Weatherall, Jane Anderson & Shazia AfridiBiogen: SMA in Adults: A UK perspective.
                                                
                                               
                                11:15am 
                                    
                                        Plenary Session 3: Intimate connections   
                                        Chair: Matt Jones 
                                            Return of the spirochaete:Margaret Kingston, ManchesterDopaminergic therapies and PD: time for a new direction?:Oliver Rascol, Toulouse 
                                12:15pm 
                                    
                                         President's Lecture: Circuits and ConnectionsTom Warner   
                                1pm 
                                    
                                        Clinicopathological conference and closeChair: Richard Davenport Discussant: Paul Reading  The Great Reveal: Marija Cauchi  
		
	
	
	 |